Literature DB >> 20660059

Treatment for advanced and recurrent endometrial carcinoma: combined modalities.

J Alejandro Rauh-Hain1, Marcela G Del Carmen.   

Abstract

Women with recurrent or advanced endometrial cancer constitute a heterogeneous group of patients. Depending on previous treatment, women with recurrent endometrial cancer may be appropriate candidates for surgery, radiation therapy, hormonal therapy, or chemotherapy. Women with advanced stage disease at presentation may also be appropriate candidates for systemic and local therapies. We review the treatment options available to treat recurrent and locally advanced endometrial cancer. Treatment choice depends largely on the localization of disease, the patient's performance status and previous treatment history, as well the tumor's hormonal receptor status. Radiation therapy is appropriate for isolated vaginal recurrences in patients with no previous history of radiation therapy. Patients with recurrent low-grade tumors overexpressing estrogen and progesterone receptors may be treated with progestin therapy. Systemic therapy is appropriate for patients with disseminate recurrences or advanced stage disease at presentation, or for those with receptor-negative tumors. We review all these different treatment strategies available to patients with advanced or recurrent endometrial cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20660059      PMCID: PMC3228028          DOI: 10.1634/theoncologist.2010-0091

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  71 in total

1.  Salvage cytoreductive surgery for recurrent endometrial cancer.

Authors:  Robert E Bristow; Antonio Santillan; Marianna L Zahurak; Ginger J Gardner; Robert L Giuntoli; Deborah K Armstrong
Journal:  Gynecol Oncol       Date:  2006-05-02       Impact factor: 5.482

2.  Progestational agents in the treatment of carcinoma of the endometrium.

Authors:  R M KELLEY; W H BAKER
Journal:  N Engl J Med       Date:  1961-02-02       Impact factor: 91.245

3.  Major progress for a less common cancer.

Authors:  Gini F Fleming
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

4.  Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes.

Authors:  Sean C Dowdy; Andrea Mariani; William A Cliby; Michael G Haddock; Ivy A Petersen; Franklin H Sim; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2006-05       Impact factor: 5.482

5.  Pelvic exenteration for recurrent endometrial cancer.

Authors:  R R Barakat; N A Goldman; D A Patel; E S Venkatraman; J P Curtin
Journal:  Gynecol Oncol       Date:  1999-10       Impact factor: 5.482

6.  Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.

Authors:  D Bafaloukos; G Aravantinos; G Samonis; G Katsifis; C Bakoyiannis; D Skarlos; P Kosmidis
Journal:  Oncology       Date:  1999-04       Impact factor: 2.935

7.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

Authors:  P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

8.  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

Authors:  Marcus E Randall; Virginia L Filiaci; Hyman Muss; Nick M Spirtos; Robert S Mannel; Jeffrey Fowler; J Tate Thigpen; Jo Ann Benda
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

Review 9.  Interstitial brachytherapy for vaginal recurrences of endometrial carcinoma.

Authors:  K Tewari; F Cappuccini; W R Brewster; P J DiSaia; M L Berman; A Manetta; A Puthawala; A M Nisar Syed; M F Kohler
Journal:  Gynecol Oncol       Date:  1999-09       Impact factor: 5.482

10.  A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.

Authors:  Linda R Duska; Ross Berkowitz; Ursula Matulonis; Michael Muto; Annekathryn Goodman; James F McIntyre; Amber Klein; Tina Atkinson; Michael V Seiden; Susana Campos
Journal:  Gynecol Oncol       Date:  2005-01       Impact factor: 5.482

View more
  18 in total

1.  Survival benefit of pelvic and paraaortic lymphadenectomy in high-grade endometrial carcinoma: a retrospective population-based cohort analysis.

Authors:  Thomas Papathemelis; S Scharl; K Kronberger; M Gerken; A Scharl; A Pauer; M Klinkhammer-Schalke
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-24       Impact factor: 4.553

2.  Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling.

Authors:  Jianjun Han; Lu Zhang; Hui Guo; Weiya Z Wysham; Dario R Roque; Adam K Willson; Xiugui Sheng; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2015-06-30       Impact factor: 5.482

3.  Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy.

Authors:  Deanna M Janzen; Miguel A Rosales; Daniel Y Paik; Daniel S Lee; Daniel A Smith; Owen N Witte; M Luisa Iruela-Arispe; Sanaz Memarzadeh
Journal:  Cancer Res       Date:  2013-06-06       Impact factor: 12.701

4.  Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study.

Authors:  Lino M Sawicki; Julian Kirchner; Johannes Grueneisen; Verena Ruhlmann; Bahriye Aktas; Benedikt M Schaarschmidt; Michael Forsting; Ken Herrmann; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-21       Impact factor: 9.236

5.  Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.

Authors:  Deanna M Janzen; Daniel Y Paik; Miguel A Rosales; Brian Yep; Donghui Cheng; Owen N Witte; Huseyin Kayadibi; Christopher M Ryan; Michael E Jung; Kym Faull; Sanaz Memarzadeh
Journal:  Mol Cancer Ther       Date:  2013-11-12       Impact factor: 6.261

6.  Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.

Authors:  Sebastien Taurin; Chieh-Hsiang Yang; Maria Reyes; Sungpil Cho; Demetrius M Coombs; Elke A Jarboe; Theresa L Werner; C Matthew Peterson; Margit M Janát-Amsbury
Journal:  Int J Gynecol Cancer       Date:  2018-01       Impact factor: 3.437

7.  Nomegestrol Acetate Suppresses Human Endometrial Cancer RL95-2 Cells Proliferation In Vitro and In Vivo Possibly Related to Upregulating Expression of SUFU and Wnt7a.

Authors:  A-Ying Ma; Shu-Wu Xie; Jie-Yun Zhou; Yan Zhu
Journal:  Int J Mol Sci       Date:  2017-06-22       Impact factor: 5.923

8.  Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer.

Authors:  Kaoru Yamawaki; Tatsuya Ishiguro; Yutaro Mori; Kosuke Yoshihara; Kazuaki Suda; Ryo Tamura; Masayuki Yamaguchi; Masayuki Sekine; Katsunori Kashima; Masaya Higuchi; Masahiro Fujii; Koji Okamoto; Takayuki Enomoto
Journal:  Cancer Sci       Date:  2017-04-19       Impact factor: 6.716

9.  The Impact of Lymphovascular Space Invasion on Recurrence and Survival in Iranian Patients With Early Stage Endometrial Cancer.

Authors:  Setareh Akhavan; Azar Ahmadzadeh; Azamsadat Mousavi; Mitra Modares Gilany; Zohreh Kazemi; Fakher Rahim; Elham Shirali
Journal:  World J Oncol       Date:  2016-09-03

10.  Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer.

Authors:  Jatinder Dhami; Kim M Hirshfield; Shridar Ganesan; Mira Hellmann; Veronica Rojas; Judith K Amorosa; Gregory M Riedlinger; Hua Zhong; Siraj M Ali; Dean Pavlick; Julia A Elvin; Lorna Rodriguez-Rodriguez
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.